Lightnews — Scholar-powered news

International Kidney Cancer Coalition @ikccorg.bsky.social · 2d

We join with Digestive Cancers Europe and others around the world in recognising #WorldMentalHealthDay.

We’re proud to be involved with the #DISCERN project, which aims to discover the causes of three poorly understood cancers in Europe. Learn more below.

@digestivecancerseu.bsky.social

Digestive Cancers Europe @digestivecancerseu.bsky.social · 2d

At DiCE, we proudly support initiatives like #DISCERN that seek to unravel the causes of complex cancers like CRC, renal, and pancreatic.

On #WorldMentalHealthDay, we honour the courage and resilience of everyone navigating cancer screening, diagnosis, or treatment.

International Kidney Cancer Coalition @ikccorg.bsky.social · 3d

We’re looking forward to #ESMO25 in Berlin! The IKCC team will include Dr Eric Jonasch, Claudia Ungarelli, Caleb Egwuenu and Olivier Exertier. Let’s connect!

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 11d

📣 #ESMO25: Experience new programme tracks that address the most pressing challenges in oncology today and empower you to drive meaningful innovation in your practice.

Oncology is changing – and so are we.👉 Register today!

🔗 https://ow.ly/bx3R50X4cqQ

1

International Kidney Cancer Coalition @ikccorg.bsky.social · 9d

She covered many important topics, such as networking, funding, budget cycles, general guidelines, and regulations. Thank you, Margie, for sharing your valuable experience. (2/2)

International Kidney Cancer Coalition @ikccorg.bsky.social · 9d

Board member Margie Hickey led the IKCC quarterly Connect and Share webinar, with participants joining from four continents. The topic discussed was how to work with the pharmaceutical industry. (1/2)

1

International Kidney Cancer Coalition @ikccorg.bsky.social · 10d

We had many good meetings last week, including with AstraZeneca in Washington, DC. We discussed priorities and collaborations related to #KidneyCancer for the upcoming year.

International Kidney Cancer Coalition @ikccorg.bsky.social · 12d

Last Thursday, IKCC met in Philadelphia with the Merck-MSD team to discuss priorities and collaborations related to #KidneyCancer in 2026.

International Kidney Cancer Coalition @ikccorg.bsky.social · 12d

IKCC met last Wednesday in Princeton, New Jersey, USA, with the team at Bristol Myers Squibb to discuss priorities for 2026 related to #KidneyCancer.

1

International Kidney Cancer Coalition @ikccorg.bsky.social · 15d

IKCC Board members and our Executive Director met the KidneyCAN team in Philadelphia this week. During our working trip in the US, we discussed Bryan Lewis’s efforts to raise funds for #KidneyCancer research there. Congratulations on your dedication and engagement. @kidneycan.bsky.social

1 2

International Kidney Cancer Coalition @ikccorg.bsky.social · 15d

Our latest newsletter is now available! It includes details on a new look for IKCC, new members of the Board of Directors, results from World Kidney Cancer Day, and more. mailchi.mp/ikcc/newslet... #KidneyCancer

News from the IKCC

mailchi.mp

Reposted by International Kidney Cancer Coalition

Deb Maskens @debmaskens.bsky.social · 19d

Really look forward to further exploration of "intentional non-adherence" within the context of quality of life goals and RWE with oral therapies. Think we all accept that current HRQoL tools/data are not telling the full picture.
#kidneycancer

1 1

International Kidney Cancer Coalition @ikccorg.bsky.social · 16d

We are pleased to share the new IKCC visual identity. This is the first brand refresh since the Coalition was founded 16 years ago this month. It is a modernised look and represents IKCC’s mission + values and meets current accessibility standards. Learn more: www.linkedin.com/pulse/new-lo...

2

International Kidney Cancer Coalition @ikccorg.bsky.social · 18d

Investment in innovation is essential to driving progress across borders, across systems, and across lives. #WorldCancerResearchDay (2/2)

1

International Kidney Cancer Coalition @ikccorg.bsky.social · 18d

In light of the increasing incidence of #KidneyCancer globally, IKCC affirms its commitment to collaborative, well-funded research as a cornerstone of improving outcomes for people living with kidney cancer. (1/2)

1

International Kidney Cancer Coalition @ikccorg.bsky.social · 19d

Reasons given for not following the prescribed treatment dose included to reduce side effects (64%), not feeling well (43%), interference with plans (31%) and running out of medication (21%).

Read the 2025 GPS Highlights Report at: ikcc.org/wp-content/u... #KidneyCancer (3/3)

1

International Kidney Cancer Coalition @ikccorg.bsky.social · 19d

When a treatment is self-administered and taken at home, such as oral targeted therapies, adhering to the medical instructions is important to help avoid poorer health outcomes like disease progression. (2/3)

1

International Kidney Cancer Coalition @ikccorg.bsky.social · 19d

According to the 2025 Global Patient Survey, 96% of respondents have received at least one type of treatment, with 76% reporting surgery, 41% immunotherapy and 37% oral targeted therapies. (1/3)

1

Reposted by International Kidney Cancer Coalition

Deb Maskens @debmaskens.bsky.social · 23d

Great model here of an international Patient Advisory Board for this Phase 3 #clinicaltrial for 1st line #kidneycancer. Important focus on improving HRQoL measures so that items are meaningful and relevant in era of immunotherapy. Great collaboration!
#patientengagement

1 2

International Kidney Cancer Coalition @ikccorg.bsky.social · 23d

More information is available at care1project.com #KidneyCancer (3/3)

International Kidney Cancer Coalition @ikccorg.bsky.social · 23d

They also heard from Professor Laurence Albiges (CARE1 Global Project Coordinator and member of the IKCC Medical Advisory Board) about patient recruitment and the innovative way that kidney cancer patients in the trial can report and manage potential side effects. (2/3)

1

International Kidney Cancer Coalition @ikccorg.bsky.social · 23d

The CARE1 Pragmatic Clinical Trial hosted a meeting of its Patient Advisory Board earlier this week. The members of the board, led by IKCC Ambassador Rose Woodward, welcomed new advocates from Italy and Greece. (1/3)

2 1

International Kidney Cancer Coalition @ikccorg.bsky.social · 24d

Join us in recognising #WorldPatientSafetyDay and this year’s slogan of “Patient safety from the start!” Learn more: www.who.int/campaigns/wo... #KidneyCancer

World Patient Safety Day 2025

This year, the theme is “Safe care for every newborn and every child”, with the slogan “Patient safety from the start!”, recognizing the vulnerability of this age group to risks and harm caused by uns...

www.who.int

International Kidney Cancer Coalition @ikccorg.bsky.social · 27d

A number of IKCC Partner Organisations are focused on childhood cancers including the Cancer Warriors Foundation, Joey's Wings Foundation, the Wilms Cancer Foundation, among others. Learn more about all our Partner Organisations: ikcc.org/about-ikcc/o... #ChildhoodCancerAwarenessMonth (2/2)

International Kidney Cancer Coalition @ikccorg.bsky.social · 27d

Malignant renal tumours represent 5% of all cancers occurring before age 15. The major specific types are nephroblastoma (also known as Wilms tumour), rhabdoid renal tumour, kidney sarcomas, and renal carcinomas. Wilms tumour is the most common renal tumour in children. (1/2)

1

Reposted by International Kidney Cancer Coalition

ACTION KIDNEY CANCER @actionkidneycancer.bsky.social · Sep 10

I is for.....

In our own words, in this series of videos, kidney cancer patients and carers talk frankly about their experiences, emotions and how to live well with a diagnosis of #kidneycancer

Watch the videos:

actionkidneycancer.org/help.../in-o...

#bypatientsforpatients #StrongerTogether

1 1

Reposted by International Kidney Cancer Coalition

ACTION KIDNEY CANCER @actionkidneycancer.bsky.social · Sep 9

Benmelstobart a new immunotherapy, which blocks the action of the immunosuppressant, PD-L1, in combination with a TKI called anlotinib was compared with sunitinib as first-line treatment for advanced #kidneycancer
Read More:
actionkidneycancer.org/first-line-b...

First-line benmelstobart plus anlotinib versus sunitinib in advanced kidney cancer - Action Kidney Cancer

A new immunotherapy called benmelstobart, which blocks the action of the immunosuppressant, PD-L1, in combination with a tyrosine kinase inhibitor (TKI) called anlotinib was compared with sunitinib as...

actionkidneycancer.org

1 1